華瑞股份(300626.SZ):子公司寧波勝克獲得武器裝備質量管理體系認證證書
格隆匯 7 月 13日丨華瑞股份(300626.SZ)公佈,公司的全資子公司寧波勝克換向器有限公司(“寧波勝克”),於近日收到北京天一正認證中心有限公司頒發的《武器裝備質量管理體系認證證書》,質量管理體系認證範圍:電機換向器的設計與製造,有效期至:2023年06月27日。
此次獲得《武器裝備質量管理體系認證證書》表明子公司寧波勝克產品質量管理體系已符合武器裝備質量管理體系的國家軍用標準,具備相關領域軍品研發、生產和服務的能力。該項認證有利於公司拓展軍工領域相關市場,提升公司綜合競爭力。該項認證暫未對公司經營業績產生重大影響,敬請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.